EV Biologics Updates on NFT Warrant Dividend Distribution
EV Biologics Updates on NFT Warrant Dividend Distribution
NASHVILLE, TN / ACCESSWIRE / August 30, 2021 / EV Biologics Corp, (OTC Pink:YECO), today updated shareholders with further details about its NFT Warrant Dividend distribution.
田納西州納什維爾/ACCESSWIRE/2021年8月30日/EV Biologics Corp(場外交易粉色代碼：YECO)今天向股東通報了有關其NFT認股權證股息分配的進一步細節。
The Company is currently finalizing its filing with FINRA, and then will have its transfer agent issue the dividend Warrant through DTC. As previously announced, YECO's shareholders-of-record on July 30, 2021, will receive a Warrant to exercise their right to accept ownership of the NFT.
該公司目前正在最後敲定向FINRA提交的文件，然後將讓其轉讓代理通過DTC發行紅利認股權證。正如之前宣佈的那樣，2021年7月30日，YECO登記在冊的股東將收到認股權證，以行使他們接受NFT所有權的權利。
The Company will distribute one (1) Warrant for every 100 shares of YECO common stock held. Each Warrant will be exercisable for one (1) NFT worth $300. Shareholders will have until (December 1, 2021) to exercise their Warrant(s) to receive their NFT(s). Shareholders possessing less than 100 shares will not be eligible for this special dividend.
本公司將為持有的每100股YECO普通股派發一(1)份認股權證。每份認股權證可行使一(1)新台幣，價值300美元。股東將在2021年12月1日之前行使他們的認股權證，以獲得他們的NFT。持股少於100股的股東將沒有資格獲得這一特別股息。
The Company will confirm when the Warrant is distributed.
本公司將確認認股權證何時分發。
About the Company
關於本公司
EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, intent on developing and enhancing the intrinsic therapeutic activity of mesenchymal stromal cell (MSC) secreted factors, as well as targeted delivery of bioactive molecules using engineered exosomes. The company is working to optimize cell lines for production of native bioactive nanoparticles and to establish an exosome engineering platform to enhance specific therapeutic activity. Initially, these novel regenerative products will be produced for preclinical research on a number of clinical indications. Using proprietary and patentable technologies, the Company is creating exclusive IP and IT inherent in these bioengineered products. Further product development will be focused on investigation of novel stem cell-derived biopharmaceuticals designed for specific clinical conditions.
EV Biologics(前身為玉龍生態材料有限公司)是一家總部位於美國懷俄明州的生物技術公司，致力於開發和增強間充質基質細胞(MSC)分泌因子的內在治療活性，並利用工程外泌體靶向輸送生物活性分子。該公司正在努力優化細胞系，以生產天然生物活性納米顆粒，並建立一個外體工程平台，以增強特定的治療活性。最初，這些新的再生產品將用於一些臨牀適應症的臨牀前研究。利用專有和專利技術，該公司正在創造這些生物工程產品固有的獨家知識產權和信息技術。進一步的產品開發將集中在針對特定臨牀條件設計的新型幹細胞衍生生物藥物的研究上。
Forward-Looking Statements
前瞻性陳述
This news release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company's financial position and business strategy. The words or phrases "plans," "would be," "will allow," "intends to," "may result," "are expected to," "will continue," "anticipates," "expects," "estimate," "project," "indicate," "could," "potentially," "should," "believe," "think," "considers" or similar expressions are intended to identify "forward-looking statements." These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
本新聞稿包含前瞻性陳述，特別是與公司業務計劃有關的陳述，以及與公司財務狀況和業務戰略有關的目標、計劃和預測的陳述。“計劃”、“將是”、“將允許”、“打算”、“可能結果”、“預計將”、“將繼續”、“預期”、“預期”、“估計”、“項目”、“表明”、“可能”、“可能”、“應該”、“相信”、“思考”、“考慮”或類似的表述旨在識別“前瞻性陳述”。這些前瞻性陳述符合1933年“證券法”第27A節和1934年“證券法”第21E節的含義，並受這兩節所創造的安全港的約束。由於一些風險和不確定因素，實際結果可能與前瞻性陳述中預測的結果大不相同。此類前瞻性表述基於當前預期，涉及已知和未知風險、對第三方信息的依賴程度、可能被取消的交易或訂單，以及其他可能導致我們的實際結果、業績或成就或行業發展與此類前瞻性表述明示或暗示的預期結果、業績或成就大不相同的因素。可能導致實際結果與預期結果大相徑庭的因素包括與當地、地區和全球經濟狀況波動有關的風險和不確定性、管理層和員工的表現、我們獲得融資的能力、競爭等。, 一般經濟狀況和其他因素在我們的定期報告和我們不時提交給美國證券交易委員會(Securities And Exchange Commission)的文件中都有詳細説明。本文中所作的陳述是截至本新聞稿發佈之日的陳述，不應作為後續任何日期的依據，公司明確表示不承擔任何義務更新任何前瞻性陳述，以反映該陳述發表之日之後發生的事件、事態發展、意想不到的事件或情況。
YECO has 7.22 million shares issued and outstanding with a float of 1,016,375 shares.
YECO有722萬股已發行和流通股，流通股為1,016,375股。
Contact:
聯繫方式：
Dennis Burns
Investor Relations
Tel (567)237-4132
dburns@nvestrain.com
丹尼斯·伯恩斯投資者關係電話(567)237-4132郵箱：dburns@nvestrain.com
For more information on EV Biologics please visit:
有關EV Biologics的更多信息，請訪問：
www.evbiologics.com
Www.evbiologics.com
SOURCE: EV Biologics, Inc.
資料來源：EV Biologics，Inc.